EA202091732A1 - Конструкты нуклеиновых кислот и вакцины из больших и малых т-антигенов полиомавируса клеток меркеля и способы их применения - Google Patents

Конструкты нуклеиновых кислот и вакцины из больших и малых т-антигенов полиомавируса клеток меркеля и способы их применения

Info

Publication number
EA202091732A1
EA202091732A1 EA202091732A EA202091732A EA202091732A1 EA 202091732 A1 EA202091732 A1 EA 202091732A1 EA 202091732 A EA202091732 A EA 202091732A EA 202091732 A EA202091732 A EA 202091732A EA 202091732 A1 EA202091732 A1 EA 202091732A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
mcv
antigens
nucleic acid
poliomavirus
Prior art date
Application number
EA202091732A
Other languages
English (en)
Inventor
Дэвид Б. Уэйнер
Элизабет Дюперре
Original Assignee
Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи filed Critical Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи
Publication of EA202091732A1 publication Critical patent/EA202091732A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Молекулы и композиции нуклеиновых кислот, содержащие одну или более нуклеотидных последовательностей, кодирующих консенсусный T-антиген полиомавируса клеток Меркеля (MCV). Раскрыты иммуномодулирующие способы и способы индукции иммунного ответа против MCV. Раскрыт способ лечения инфекции MCV и способы лечения или профилактики карциномы клеток Меркеля, связанной с MCV. Раскрыты модифицированные консенсусные T-антигены MCV.
EA202091732A 2018-01-19 2019-01-18 Конструкты нуклеиновых кислот и вакцины из больших и малых т-антигенов полиомавируса клеток меркеля и способы их применения EA202091732A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862619161P 2018-01-19 2018-01-19
PCT/US2019/014171 WO2019143921A2 (en) 2018-01-19 2019-01-18 Large and small t antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same

Publications (1)

Publication Number Publication Date
EA202091732A1 true EA202091732A1 (ru) 2020-09-10

Family

ID=67302504

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091732A EA202091732A1 (ru) 2018-01-19 2019-01-18 Конструкты нуклеиновых кислот и вакцины из больших и малых т-антигенов полиомавируса клеток меркеля и способы их применения

Country Status (11)

Country Link
US (2) US11524065B2 (ru)
EP (1) EP3740226A4 (ru)
JP (1) JP7485604B2 (ru)
KR (1) KR20200110678A (ru)
CN (1) CN111801111A (ru)
AU (1) AU2019210063A1 (ru)
BR (1) BR112020014632A2 (ru)
CA (1) CA3088374A1 (ru)
EA (1) EA202091732A1 (ru)
MX (1) MX2020007676A (ru)
WO (1) WO2019143921A2 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020014632A2 (pt) * 2018-01-19 2021-01-05 The Wistar Institute Of Anatomy And Biology Composição imunogênica, molécula de ácido nucleico codificando um peptídeo, peptídeo, métodos para induzir uma resposta imune contra um antígeno t de mcv em um sujeito em necessidade do mesmo e para tratamento ou prevenção de uma patologia associada a mcv no sujeito em necessidade do mesmo.
WO2021247534A2 (en) * 2020-06-01 2021-12-09 The Broad Institute, Inc. Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1549730A (zh) 2000-10-04 2004-11-24 ���������Ǵ�ѧ�й��� 黄病毒和瘟病毒衣壳蛋白的组成和使用方法
WO2016073595A1 (en) * 2014-11-05 2016-05-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services T cells and dendritic cells for polyomavirus therapy
EP3101134A1 (en) 2015-06-05 2016-12-07 Apcure SAS Therapeutic vaccine for treating or preventing merkel cell polyoma virus-associated tumors
WO2017060283A1 (en) 2015-10-06 2017-04-13 Universität Basel Specific immunodominant peptide epitopes for polyomavirus vaccine
BR112020014632A2 (pt) * 2018-01-19 2021-01-05 The Wistar Institute Of Anatomy And Biology Composição imunogênica, molécula de ácido nucleico codificando um peptídeo, peptídeo, métodos para induzir uma resposta imune contra um antígeno t de mcv em um sujeito em necessidade do mesmo e para tratamento ou prevenção de uma patologia associada a mcv no sujeito em necessidade do mesmo.

Also Published As

Publication number Publication date
US11524065B2 (en) 2022-12-13
US20200345830A1 (en) 2020-11-05
CN111801111A (zh) 2020-10-20
EP3740226A4 (en) 2021-10-13
AU2019210063A1 (en) 2020-08-20
WO2019143921A2 (en) 2019-07-25
KR20200110678A (ko) 2020-09-24
WO2019143921A3 (en) 2020-04-09
EP3740226A2 (en) 2020-11-25
JP7485604B2 (ja) 2024-05-16
JP2021511320A (ja) 2021-05-06
MX2020007676A (es) 2020-11-12
CA3088374A1 (en) 2019-07-25
US20230201328A1 (en) 2023-06-29
BR112020014632A2 (pt) 2021-01-05

Similar Documents

Publication Publication Date Title
CY1121215T1 (el) Αντιικα εμβολια με βελτιωμενη κυτταρικη ανοσογονικοτητα
MX2020004578A (es) Composiciones de casz y metodos de uso.
EA202092808A1 (ru) Вакцины на основе наночастиц с новыми структурными компонентами
EA201990861A1 (ru) Рнк-направляемые модифицирующие нуклеиновые кислоты ферменты и способы их применения
EA201890355A1 (ru) Новые способы индукции иммунного ответа
BR112017003108A2 (pt) anticorpo ou fragmento de ligação a antígeno do mesmo, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos para produção de um anticorpo ou fragmento de ligação a antígeno, para tratamento de câncer e de uma infecção ou doença infecciosa, para detecção da presença de um peptídeo de tigit ou um fragmento do mesmo e para aumentar a atividade de uma célula imune e a atividade antitumoral de um anticorpo anti-tigit, vacina, e, uso de um anticorpo ou fragmento de ligação a antígeno
EA201791148A1 (ru) Способ определения абсолютных количеств hla-рестриктированных раковых пептидов, образовавшихся в результате естественного процессинга
EA201990937A1 (ru) Цитомегаловирусные векторы, выбирающие t-клетки, ограниченные по молекулам главного комплекса гистосовместимости e
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
SG10201901053TA (en) Novel tilapia virus and uses thereof
EA201690529A1 (ru) Способы модификации клетки-хозяина
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
WO2019226939A8 (en) Immune checkpoint inhibitor co-expression vectors
EA202091732A1 (ru) Конструкты нуклеиновых кислот и вакцины из больших и малых т-антигенов полиомавируса клеток меркеля и способы их применения
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
WO2016130628A8 (en) Griffithsin mutants
EA201691981A1 (ru) Улучшенные транспортные молекулы модулярного антигена и их применение
EA201990711A1 (ru) Новый ehv сайт инсерции orf70
EA202192923A1 (ru) Антитела и способы лечения инфекции, вызываемой вирусом гриппа а
EA201990719A1 (ru) Новые промоторы
MX2023003934A (es) Antigenos de consenso de filovirus, construcciones de acido nucleico y vacunas realizadas a partir de estos, y metodos para utilizarlos.
EA202090628A1 (ru) Система экспрессии paramyxoviridae
WO2020065349A3 (en) Vaccines and methods
EA202190758A1 (ru) Композиция для индукции гибели клеток, имеющих мутированный ген, и способ индукции гибели клеток, имеющих мутированный ген, с применением композиции
BR112016030008A2 (pt) método para a detecção de infecção por pegivirus humano 2 em um indivíduo, para a detecção de ácido nucleico de pegivirus humano 2 e para a detecção de pegivirus humano 2 em uma amostra, e, composição